T-cell Modulatory Multimeric Polypeptides for Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face challenges in selectively modulating T-cell responses, often leading to non-specific activation or inhibition, which can result in unintended immune reactions and reduced efficacy against targeted antigens.
Innovation Solution
Development of T-cell modulatory multimeric polypeptides (TMMPs) comprising an immunomodulatory polypeptide, class I HLA polypeptides, a peptide epitope, and a tumor-targeting polypeptide, designed to specifically bind to T-cell receptors and modulate T-cell activity, enhancing epitope-specific responses while minimizing non-specific interactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immunotherapies are used to modulate T-cell responses, then T-cell activity can be activated or inhibited, but non-specific activation or inhibition occurs leading to unintended immune reactions
Solution Approach 1:
The immunomodulatory polypeptide is divided into separate functional components: a tumor-targeting polypeptide (scFv) that binds to tumor antigens, and an immunomodulatory domain (MOD) that provides T-cell modulation. This segmentation allows each component to perform its specific function independently, ensuring tumor-specific modulation without non-specific activation.
Solution Approach 2:
The TMMP is designed with localized functionality where the scFv portion targets specific tumor antigens on cancer cells, while the MOD portion provides epitope-specific T-cell modulation only at the tumor site. This local quality ensures that T-cell modulation occurs specifically at the tumor location rather than systemically, reducing non-specific immune reactions.
2Measurement precision
If costimulatory proteins are used for T-cell activation, then T-cell specificity can be driven, but the costimulatory protein is not epitope specific and is generally expressed on all T cells or large T cell subsets
Solution Approach 1:
The TMMP separates the epitope recognition function (performed by the scFv binding to tumor antigens) from the T-cell modulation function (performed by the MOD). This segmentation allows epitope-specific modulation without requiring broad T-cell subset engagement, as the scFv first selects for tumor-specific cells before the MOD activates the T cells.
Solution Approach 2:
The scFv acts as an intermediary that first binds to tumor antigens on cancer cells, thereby selecting for tumor-specific T cells before the MOD provides costimulatory signals. This intermediary step ensures that only tumor-specific T cells are activated, eliminating the need for broad T-cell subset engagement.
3Reliability
If multimeric polypeptides are designed with multiple components, then epitope-specific and tumor-targeted responses can be achieved, but the structure becomes complex
Solution Approach 1:
The patent combines the scFv and MOD into a single multimeric polypeptide structure where the scFv and MOD are linked together. This merging allows the tumor-targeting and immunomodulatory functions to be delivered in a single molecular entity, simplifying administration while maintaining epitope-specific response.
Solution Approach 2:
The TMMP is designed as a multi-functional molecule that simultaneously performs tumor targeting (via scFv binding to tumor antigens), epitope recognition (via MOD presenting epitopes to TCRs), and T-cell modulation (via MOD providing costimulatory signals). This multi-functionality in a single molecule reduces the need for multiple separate agents, simplifying the overall therapy structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
TMMPs effectively modulate T-cell activity, increasing epitope-specific responses and cytotoxic activity against cancer cells, while reducing non-specific immune activation, thereby improving the therapeutic index of immunotherapies.
Implementation Method 1
engagement of the T cell receptor (TCR), present on the surface of a T cell, with a small peptide antigen non-covalently presented on the surface of an antigen presenting cell
Implementation Method 2
engagement of costimulatory proteins found on the APC with counterpart costimulatory proteins the T cells
Data Source
AI summary
The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) that comprise an immunomodulatory polypeptide, class I HLA polypeptides (a class I HLA heavy chain polypeptide and a β2 microglobulin polypeptide), a peptide that presents an epitope to a T-cell receptor, and a tumor-targeting polypeptide. A TMMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.